Physician profile
Abbigale J E Wilson
NPI 1760702161
$1,989.09
in general payments reported to CMS, 2019-2025
29 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $351 · 2021: $356 · 2022: $403 · 2023: $189 · 2024: $113 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $326.60 | 2020-2024 | Trelegy Ellipta |
| Abbvie INC. | $248.30 | 2021-2025 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $159.20 | 2019-2025 | Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $119.52 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $114.97 | 2019-2023 | |
| Lilly USA, LLC | $113.52 | 2020-2025 | Jardiance, Zepbound |
| Amgen INC. | $97.35 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $89.28 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $71.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $62.19 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.21 | 2019-2022 | |
| Allergan, INC. | $50.18 | 2020 | |
| Novo Nordisk INC | $47.47 | 2020-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $42.63 | 2019-2021 | |
| Verona Pharma, INC. | $42.42 | 2025 | Ohtuvayre |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $38.47 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.36 | 2023-2025 | Xifaxan |
| Eisai INC. | $34.17 | 2020-2021 | |
| Astellas Pharma US INC | $32.93 | 2019-2022 | |
| Sanofi Pasteur INC. | $29.73 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $28.29 | 2019-2025 | Eliquis |
| Ironshore Pharmaceuticals INC. | $27.13 | 2019 | |
| Horizon Therapeutics Plc | $23.88 | 2022 | |
| Dexcom, INC. | $22.59 | 2023 | Dexcom G6 Transmitter |
| Tris Pharma INC | $17.20 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.94 | 2019 | |
| Exact Sciences Corporation | $15.12 | 2025 | Cologuard Collection Kit |
| Ucb, INC. | $14.24 | 2019 | |
| Mylan Specialty L.P. | $13.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbigale Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.